DC-CIK联合化疗治疗晚期胃癌地近期疗效观察.docVIP

DC-CIK联合化疗治疗晚期胃癌的近期疗效观察 【摘要】目的 探讨树突状细胞（dendritic cell，The safety were observed. Results The ratios of CD3+,CD4+,CD56+andCD4+/CD8+ were not change obviously in combined treatment group and decreased in control group after treatment, which showed significant statistical difference (P0.05) .The IL-12 and IFN-γ were increased after treatment in combined treatment group, (P0.05). The IL-2, IL-12 and TNF-αwere decreased in control group after treatment, (P0.05). The disease control rate (DCR) of combined therapy group and control group were 78.6%and 53.6%respectively showing significant difference (P0.05).The effective rate of KPS were 82.14%and 57.14%respectively showing significant difference (P0.05). Conclusion:DC-CIK cells combined with chemotherapy can improve immune functions and elevate life quality of the patients. DC-CIK cells combined with chemotherapy is likely to be an effective adoptive immunotherapy for gastric cancer 【key words】dendritic cells; cytokine induced killer cells; gastric cancer 我国胃癌病人诊断时85%处于晚期[1]，手术、化疗、放疗等传统治，其 5 年生存率仍%[3]，由于characteristics in two groups 临床特征 例数 分组 ｘ2 P 联合治疗组（%） 对照组（%） 性别 男 43 21(75.0) 22(78.6) 0.1 ＞0.05 女 13 7(25.0) 6(21.4) 中位年龄（岁） 59（36~79） 62（41~77） 58（36~79） 胃癌部位 贲门部 21 10（35.7） 11（39.2） 胃体部 23 13（46.4） 10（35.7） 0.772 ＞0.05 胃窦部 12 5（17.9） 7（25.0） 病理类型 低分化腺 13 7（25.0） 6（21.4） 中分化腺 36 17 （60.7） 19（67.9） 0.331 ＞0.05 粘液腺 7 4（14.3） 3（10.7） 术后复发转移/晚期（例） 30/26 17/11 13/15 转移部位 肝